<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id><journal-id journal-id-type="iso-abbrev">J Bras Pneumol</journal-id><journal-title-group><journal-title>Jornal Brasileiro de Pneumologia : Publica&#x000e7;&#x00061;&#x0030b;o Oficial da Sociedade Brasileira de Pneumologia e Tisilogia</journal-title></journal-title-group><issn pub-type="ppub">1806-3713</issn><issn pub-type="epub">1806-3756</issn><publisher><publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23503486</article-id><article-id pub-id-type="pmc">4075810</article-id><article-id pub-id-type="doi">10.1590/S1806-37132013000100008</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Spirometric changes in obstructive disease: after all, how
much is significant?<xref ref-type="fn" rid="fn01">*</xref>,<xref ref-type="fn" rid="fn02">**</xref>
</article-title><trans-title-group xml:lang="pt"><trans-title>Altera&#x000e7;&#x000f5;es espirom&#x000e9;tricas em doen&#x000e7;as obstrutivas: afinal, o quanto &#x000e9;
relevante?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Soares</surname><given-names>Andr&#x000e9; Luis Pinto</given-names></name><role>Assistant Professor</role><aff>Federal University of Rio Grande do Norte, Natal, Brazil. Federal University of Rio Grande do Norte, Natal,
Brazil</aff></contrib><contrib contrib-type="author"><name><surname>Pereira</surname><given-names>Carlos Alberto de Castro</given-names></name><role>Physician</role><aff>Federal University of S&#x000e3;o Paulo, Department of Pulmonology, S&#x000e3;o Paulo, Brazil. Department of Pulmonology, Federal University of S&#x000e3;o Paulo, S&#x000e3;o
Paulo, Brazil</aff></contrib><contrib contrib-type="author"><name><surname>Rodrigues</surname><given-names>Silvia Carla</given-names></name><role>Physician</role><aff>S&#x000e3;o Paulo Hospital for State Civil Servants, S&#x000e3;o Paulo, Brazil. S&#x000e3;o Paulo Hospital for State Civil Servants, S&#x000e3;o Paulo, Brazil</aff></contrib></contrib-group><author-notes><corresp id="c01"><bold>Correspondence to:</bold> Andr&#x000e9; Luis Pinto Soares Avenida Governador Juvenal
Lamartine, 326, apto. 1001, Torre 2, Tirol CEP 59020 280, Natal, RN, Brasil Tel. 55
84 4009-2030 E-mail: <email>drandrepinto@globo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2013</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2013</year></pub-date><volume>39</volume><issue>1</issue><fpage>56</fpage><lpage>62</lpage><history><date date-type="received"><day>30</day><month>8</month><year>2012</year></date><date date-type="accepted"><day>07</day><month>12</month><year>2012</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><sec><title>OBJECTIVE:</title><p> To establish the upper limits for changes in FEV<sub>1</sub>, slow vital capacity
(SVC), FVC, and inspiratory capacity (IC) after placebo administration in patients
with airflow obstruction. </p></sec><sec><title>METHODS:</title><p> One hundred and two adults with airflow obstruction (FEV<sub>1</sub> = 62 &#x000b1; 19%
of predicted) were included in the study. All of the participants performed SVC
and FVC maneuvers before and after the administration of placebo spray. The
changes in FEV<sub>1</sub>, SVC, FVC, and IC were expressed as absolute values,
percentage of change from baseline values, and percentage of predicted values, 95%
CIs and 95th percentiles being calculated. Factor analysis was performed in order
to determine how those changes clustered. </p></sec><sec><title>RESULTS:</title><p> Considering the 95% CIs and 95th percentiles and after rounding the values, we
found that the upper limits for a significant response were as follows:
FEV<sub>1</sub> = 0.20 L, FVC = 0.20 L, SVC = 0.25 L, and IC = 0.30 L
(expressed as absolute values); FEV<sub>1</sub> = 12%, FVC = 7%, SVC = 10%, and IC
= 15% (expressed as percentage of change from baseline values); and
FEV<sub>1</sub> = 7%, FVC = 6%, SVC = 7%, and IC = 12% (expressed as percentage
of predicted values). </p></sec><sec><title>CONCLUSIONS:</title><p> In patients with airflow obstruction, IC varies more widely than do FVC and SVC.
For IC, values greater than 0.30 L and 15% of change from the baseline value can
be considered significant. For FVC, values greater than 0.20 L and 7% of change
from the baseline value are significant. Alternatively, changes exceeding 0.20 L
and 7% of the predicted value can be considered significant for FEV<sub>1</sub>
and FVC. On factor analysis, spirometric parameters clustered into three
dimensions, expressing changes in flows, volumes, and dynamic hyperinflation.</p></sec></abstract><trans-abstract xml:lang="pt"><sec><title>OBJETIVO:</title><p> Estabelecer os limites superiores para mudan&#x000e7;as em VEF<sub>1</sub>, capacidade
vital lenta (CVL), CVF e capacidade inspirat&#x000f3;ria (CI) ap&#x000f3;s o uso de placebo em
pacientes com obstru&#x000e7;&#x000e3;o ao fluxo a&#x000e9;reo. </p></sec><sec><title>M&#x000c9;TODOS:</title><p> Cento e dois adultos com obstru&#x000e7;&#x000e3;o ao fluxo a&#x000e9;reo (VEF<sub>1</sub> = 62 &#x000b1; 19% do
previsto) foram inclu&#x000ed;dos neste estudo. Todos os participantes realizaram manobras
de CVL e CVF antes e depois do uso de <italic>spray</italic> de placebo. As
mudan&#x000e7;as em VEF<sub>1</sub>, CVL, CVF e CI foram expressas em valores absolutos,
porcentagem de varia&#x000e7;&#x000e3;o em rela&#x000e7;&#x000e3;o aos valores basais e porcentagem dos valores
previstos, e foram calculados os IC95% e os percentis 95. A an&#x000e1;lise fatorial foi
realizada a fim de determinar como essas altera&#x000e7;&#x000f5;es se agrupavam. </p></sec><sec><title>RESULTADOS:</title><p> Considerando os IC95% e percentis 95 e ap&#x000f3;s o arredondamento dos valores,
obtivemos os seguintes limites superiores para resposta significante:
VEF<sub>1</sub> = 0,20 L, CVF = 0,20 L, CVL = 0,25 L e CI = 0,30 L (em valores
absolutos); VEF<sub>1</sub> = 12%, CVF = 7%, CVL = 10% e CI = 15% (em porcentagem
de varia&#x000e7;&#x000e3;o em rela&#x000e7;&#x000e3;o aos valores basais) e VEF<sub>1</sub> = 7%, CVF = 6%, CVL =
7% e CI = 12% (em porcentagem dos valores previstos). </p></sec><sec><title>CONCLUS&#x000d5;ES:</title><p> Em pacientes com obstru&#x000e7;&#x000e3;o ao fluxo a&#x000e9;reo, a CI apresenta maior variabilidade do
que a CVF e a CVL. Para a CI, valores maiores que 0,30 L e 15% de varia&#x000e7;&#x000e3;o em
rela&#x000e7;&#x000e3;o ao valor basal devem ser considerados significantes. Para CVF, valores
maiores que 0,20L e 7% de varia&#x000e7;&#x000e3;o em rela&#x000e7;&#x000e3;o ao valor basal s&#x000e3;o significantes.
Alternativamente, altera&#x000e7;&#x000f5;es de mais de 0,20 L e 7% do previsto no VEF<sub>1</sub>
e na CVF devem ser consideradas significantes. Na an&#x000e1;lise fatorial, os par&#x000e2;metros
espirom&#x000e9;tricos se agruparam em tr&#x000ea;s dimens&#x000f5;es, expressando mudan&#x000e7;as no fluxo,
volume e hiperinsufla&#x000e7;&#x000e3;o din&#x000e2;mica.</p></sec></trans-abstract><kwd-group><kwd>Respiratory function tests</kwd><kwd>Spirometry</kwd><kwd>Bronchospirometry</kwd></kwd-group><counts><table-count count="4"/><ref-count count="30"/><page-count count="7"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>In patients with airflow obstruction, changes in spirometric values after bronchodilator
use are indicative of reversibility if they exceed the natural variability. On the basis
of two landmark studies,<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup> first the American Thoracic Society
(ATS)<sup>(</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>)</sup> and later the ATS/European Respiratory Society
(ERS)<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup> issued statements in which they recommended that an absolute
change of 200 mL and a relative change of 12% from baseline values be used in order to
classify bronchodilator response as significant. Those values have also been reported as
being indicative of significant changes in FVC after bronchodilator use,<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup>
being widely used.</p><p>Changes occurring after bronchodilator use can also be expressed in terms of the
percentage of predicted values.<sup>(</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>)</sup> In two studies,<sup>(</sup>
<xref rid="B06" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>,</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>
FEV<sub>1</sub> values higher than 6.0% were recommended.<sup>(</sup>
<xref rid="B06" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>,</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> In one of
those studies,<sup>(</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> an FVC value of 6.0% was recommended.</p><p>The relief of dyspnea and the increase in exercise performance after bronchodilator use
in patients with airflow obstruction are due to a reduction in lung hyperinflation, as
evidenced by increased inspiratory capacity (IC), increased vital capacity, or
both.<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>-</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> To our knowledge, a small, single-center study<sup>(</sup>
<xref rid="B06" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup>
is the only study in which the limits of variation in IC after placebo administration
were evaluated.<sup>(</sup>
<xref rid="B06" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup> Although studies have suggested a cut-off point for IC
based on a relevant increase in exercise performance,<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> it remains to be
shown whether such values exceed the normal variability.</p><p>Changes in spirometric parameters after bronchodilator use can express variations in
flow, volume, or both. The objective of the present study was to establish the upper
limits for changes in slow vital capacity (SVC) and FVC after placebo administration in
a large sample of patients with airflow obstruction, as well as to determine how those
parameters clustered on factor analysis.</p></sec><sec sec-type="methods"><title>Methods</title><p>The present study was conducted in a referral pulmonary function laboratory in the city
of S&#x000e3;o Paulo, Brazil.</p><p>All of the patients who were found to have obstructive disease were asked to return to
the laboratory for further spirometry after having discontinued the use of short- and
long-acting &#x003b2;<sub>2</sub> agonists (for &#x02265; 12 h and for &#x02265; 24 h, respectively) and of
short- and long-acting theophylline preparations (for &#x02265; 24 h and for &#x02265; 48 h,
respectively). The patients were not required to discontinue the use of corticosteroids.
The diagnosis of asthma or COPD was based on medical records made by specialists.</p><p>All of the study participants gave written informed consent, and the study protocol was
approved by the local research ethics committee.</p><p>A total of 102 adults with airflow obstruction (asthma, COPD, or both) performed SVC
maneuvers and, subsequently, FVC maneuvers. All patients had been stable in the last 30
days. Airflow obstruction was characterized by an FEV<sub>1</sub>/FVC ratio below the
5th percentile of the predicted value.</p><p>The spirometric tests were performed with a SensorMedics spirometer (Vmax229d;
SensorMedics, Yorba Linda, CA, USA), which was calibrated daily. All SVC and FVC
measurements were performed in accordance with the ATS/ERS criteria,<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup> SVC
being assessed during an expiratory maneuver.</p><p>A minimum of three acceptable SVC measurements were obtained. The difference between the
highest SVC value and the second highest SVC value was &#x0003c; 0.150 L. For SVC, the
largest value obtained from at least three acceptable maneuvers was recorded. For IC, at
least three acceptable maneuvers were performed. The difference between the largest IC
value and the second largest IC value was &#x0003c; 0.100 L. For IC, the values derived from
the largest SVC were reported. The reference values for forced spirometry and IC were
those reported in studies conducted in Brazil.<sup>(</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B08" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup> Within 15 min after the
administration of four sprays of placebo, all tests were repeated in the same order, and
the same acceptability and reproducibility criteria were applied.</p><p>General data are expressed as mean &#x000b1; SD. The spirometric changes occurring after placebo
administration are expressed as follows: absolute (post-baseline) values; percentage of
change from baseline values (post-baseline &#x000d7; 100/baseline); and percentage of predicted
values (post-baseline &#x000d7; 100/predicted).</p><p>The distribution of absolute changes induced by placebo was tested for normality by the
Kolmogorov-Smirnov test and the Shapiro-Wilk test, as well as by analysis of normality
plots, the skewness coefficient, the kurtosis coefficient, extreme values, and outliers
being assessed.<sup>(</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup> Outliers were not excluded from the analysis. Although
the variations in SVC and IC showed normal distribution, the variations in
FEV<sub>1</sub> and FVC did not. The upper limits were calculated by 95th percentiles
and 95% CIs.</p><p>The correlations of the different expressions of spirometric changes after placebo
administration with anthropometric variables were determined by Spearman's test. A
two-tailed t-test was used for between-group comparisons.</p><p>For factor analysis, a correlation matrix was constructed, and the principal components
were derived. A correlation coefficient &#x0003e; 0.30 was considered significant. Factors
with an eigenvalue &#x0003e; 1 on principal component analysis were included in varimax
rotation. For the final model, a scree plot was employed for factor selection, and three
factors were retained. The next step was to construct a new factor matrix in order to
examine the weight assigned to each variable per factor.</p><p>All statistical analyses were performed with the IBM SPSS Statistics software package,
version 17.0 (IBM Corporation, Armonk, NY, USA). Values of p &#x0003c; 0.05 were considered
statistically significant.</p></sec><sec sec-type="results"><title>Results</title><p>The clinical and spirometric data before the administration of placebo are shown in
<xref ref-type="table" rid="t01">Table 1</xref>. Patient age ranged from 25 years to
80 years. Females predominated, as did patients with a diagnosis of asthma. In 17, 35,
and 50 of the patients, respectively, FEV<sub>1</sub> was &#x02264; 40% of the predicted value,
40-59% of the predicted value, and &#x02265; 60% of the predicted value.</p><p>
<table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><title>Clinical data and pulmonary function test results before the
administration of placebo in 102 patients with airflow obstruction.</title></caption><table frame="hsides" rules="groups"><colgroup width="33%" span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-bottom: thin solid; border-top: thin solid; border-color: #000000"><tr><td rowspan="1" colspan="1">Variable</td><td rowspan="1" colspan="1">Result</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Gender </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">Male, n</td><td rowspan="1" colspan="1">39</td></tr><tr><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">Female, n</td><td rowspan="1" colspan="1">63</td></tr><tr><td rowspan="1" colspan="1">Age (years), mean &#x000b1; SD</td><td rowspan="1" colspan="1">55 &#x000b1; 11</td></tr><tr><td rowspan="1" colspan="1">Smoking status</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">Nonsmoker, n</td><td rowspan="1" colspan="1">50</td></tr><tr><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">Former smoker, n</td><td rowspan="1" colspan="1">42</td></tr><tr><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">Current smoker, n</td><td rowspan="1" colspan="1">10</td></tr><tr><td rowspan="1" colspan="1">Diagnosis </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">COPD, n</td><td rowspan="1" colspan="1">34</td></tr><tr><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">Asthma, n</td><td rowspan="1" colspan="1">64</td></tr><tr><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">COPD and asthma, n</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">FEV<sub>1</sub>/FVC% (% of predicted) mean &#x000b1; SD</td><td rowspan="1" colspan="1">56 &#x000b1; 12</td></tr><tr><td rowspan="1" colspan="1">VC (% of predicted), mean &#x000b1; SD</td><td rowspan="1" colspan="1">89 &#x000b1; 17</td></tr><tr><td rowspan="1" colspan="1">FVC (% of predicted), mean &#x000b1; SD</td><td rowspan="1" colspan="1">88 &#x000b1; 17</td></tr><tr><td rowspan="1" colspan="1">FEV<sub>1</sub> (% of predicted), mean &#x000b1; SD</td><td rowspan="1" colspan="1">62 &#x000b1; 19</td></tr><tr><td rowspan="1" colspan="1">IC (% of predicted), mean &#x000b1; SD</td><td rowspan="1" colspan="1">83 &#x000b1; 18</td></tr></tbody></table><table-wrap-foot><fn id="TFN01t01"><label>IC</label><p>: inspiratory capacity</p></fn></table-wrap-foot></table-wrap>
</p><p>There were differences between asthma and COPD patients in terms of the baseline
percentage of predicted FEV<sub>1</sub> (FEV<sub>1</sub>%). In the 64 patients with
asthma, FEV<sub>1</sub>% was 65.3 &#x000b1; 18.5, compared with 54.1 &#x000b1; 19.8 in the 34 COPD
patients (t = 2.78; p = 0.006). However, the absolute variation in FEV<sub>1</sub> after
the administration of placebo was similar between the two groups of patients: &#x02212;0.043 &#x000b1;
0.122 mL in the patients with asthma and &#x02212;0.009 &#x000b1; 0.133 mL in those with COPD (t = 1.29;
p = 0.20).</p><p>There were no differences between males and females in terms of the absolute changes in
FEV<sub>1</sub> (&#x02212;0.045 &#x000b1; 0.147 mL vs. &#x02212;0.043 &#x000b1; 0.147 mL; t = 1.50; p = 0.124).</p><p>On one-sample analysis, there was no evidence of any learning effect, the mean changes
after the administration of placebo being nonsignificantly different from zero.</p><p>
<xref ref-type="table" rid="t02">Table 2</xref> shows the means, 95% CIs, and 95th
percentiles for SVC, IC, FVC, and FEV<sub>1</sub> after the administration of placebo,
in terms of absolute values, percentage of change from baseline values, and percentage
of predicted values. After rounding the values derived from these two methods, we
obtained significant values for changes in the spirometric parameters under study (<xref ref-type="table" rid="t03">Table 3</xref>).</p><p>
<table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><title>Mean variations, 95% CIs, and 95th percentiles for the absolute values,
percentage of change from baseline values, and percentage of predicted values
for spirometric parameters after placebo administration.</title></caption><table frame="hsides" rules="groups"><colgroup width="10%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-bottom: thin solid; border-top: thin solid; border-color: #000000"><tr><td rowspan="1" colspan="1">Parameter </td><td rowspan="1" colspan="1">Absolute</td><td rowspan="1" colspan="1">% of change from baseline</td><td rowspan="1" colspan="1">% of predicted</td></tr><tr><td rowspan="1" colspan="1">Mean</td><td rowspan="1" colspan="1">95% CI</td><td rowspan="1" colspan="1">95th percentile</td><td rowspan="1" colspan="1">Mean</td><td rowspan="1" colspan="1">95% CI</td><td rowspan="1" colspan="1">95th percentile</td><td rowspan="1" colspan="1">Mean</td><td rowspan="1" colspan="1">95% CI</td><td rowspan="1" colspan="1">95th percentile</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">SVC </td><td rowspan="1" colspan="1">&#x02212;0.030</td><td rowspan="1" colspan="1">0.237</td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">&#x02212;0.890</td><td rowspan="1" colspan="1">9.5</td><td rowspan="1" colspan="1">7.5</td><td rowspan="1" colspan="1">&#x02212;0.920</td><td rowspan="1" colspan="1">7.4</td><td rowspan="1" colspan="1">6.0</td></tr><tr><td rowspan="1" colspan="1">IC</td><td rowspan="1" colspan="1">&#x02212;0.006</td><td rowspan="1" colspan="1">0.283</td><td rowspan="1" colspan="1">0.317</td><td rowspan="1" colspan="1">0.034</td><td rowspan="1" colspan="1">14.1</td><td rowspan="1" colspan="1">15.4</td><td rowspan="1" colspan="1">&#x02212;0.114</td><td rowspan="1" colspan="1">11.2</td><td rowspan="1" colspan="1">12.5</td></tr><tr><td rowspan="1" colspan="1">FVC</td><td rowspan="1" colspan="1">&#x02212;0.012</td><td rowspan="1" colspan="1">0.198</td><td rowspan="1" colspan="1">0.227</td><td rowspan="1" colspan="1">&#x02212;0.283</td><td rowspan="1" colspan="1">7.3</td><td rowspan="1" colspan="1">6.5</td><td rowspan="1" colspan="1">&#x02212;0.213</td><td rowspan="1" colspan="1">6.3</td><td rowspan="1" colspan="1">5.6</td></tr><tr><td rowspan="1" colspan="1">FEV<sub>1</sub>
</td><td rowspan="1" colspan="1">&#x02212;0.020</td><td rowspan="1" colspan="1">0.192</td><td rowspan="1" colspan="1">0.159</td><td rowspan="1" colspan="1">&#x02212;0.796</td><td rowspan="1" colspan="1">12.3</td><td rowspan="1" colspan="1">12.7</td><td rowspan="1" colspan="1">&#x02212;0.549</td><td rowspan="1" colspan="1">7.3</td><td rowspan="1" colspan="1">7.4</td></tr></tbody></table><table-wrap-foot><fn id="TFN01t02"><label>SVC</label><p>:slow vital capacity;</p></fn><fn id="TFN02t02"><label>IC</label><p>: inspiratory capacity</p></fn></table-wrap-foot></table-wrap>
</p><p>
<table-wrap id="t03" orientation="portrait" position="float"><label>Table 3</label><caption><title>Significant variations for absolute values, percentage of change from
baseline values, and percentage of predicted values for spirometric parameters
after placebo administration.</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-bottom: thin solid; border-top: thin solid; border-color: #000000"><tr><td rowspan="1" colspan="1">Variation</td><td rowspan="1" colspan="1">Absolute</td><td rowspan="1" colspan="1">% of change from baseline</td><td rowspan="1" colspan="1">% of predicted</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">SVC</td><td rowspan="1" colspan="1">0.25</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">IC</td><td rowspan="1" colspan="1">0.30</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">FVC</td><td rowspan="1" colspan="1">0.20</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">FEV<sub>1</sub>
</td><td rowspan="1" colspan="1">0.20</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">7</td></tr></tbody></table><table-wrap-foot><fn id="TFN01t03"><label>SVC</label><p>: slow vital capacity</p></fn><fn id="TFN02t03"><label>IC</label><p>: inspiratory capacity</p></fn></table-wrap-foot></table-wrap>
</p><p>Spearman's test revealed no significant correlation between changes in the spirometric
parameters and their initial values (data not shown). Similarly, there were no
correlations between changes in the spirometric parameters and age or between changes in
the spirometric parameters and height.</p><p>Significant correlations were found between changes in FEV<sub>1</sub> and changes in
FVC (r<sub>s = </sub>0.62; p &#x0003c; 0.001), between changes in SVC and changes in FVC
(r<sub>s</sub> = 0.40; p &#x0003c; 0.001), and between changes in SCV and changes in IC
(r<sub>s</sub> = 0.22; p = 0.017). By factor analysis, three factors were selected
from the scree plot, explaining 92.5% of the total variance of changes after the
administration of placebo. The first factor included changes in FEV<sub>1</sub> and FVC,
the second factor included changes in SVC and FVC, and the third factor included changes
in IC only (<xref ref-type="table" rid="t04">Table 4</xref>).</p><p>
<table-wrap id="t04" orientation="portrait" position="float"><label>Table 4</label><caption><title>Rotated component matrix for variations in spirometric parameters after
placebo administration.</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-bottom: thin solid; border-top: thin solid; border-color: #000000"><tr><td rowspan="1" colspan="1">Parameter</td><td rowspan="1" colspan="1">Component</td></tr><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">FEV<sub>1</sub>
</td><td rowspan="1" colspan="1">0.935</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">FVC</td><td rowspan="1" colspan="1">0.866</td><td rowspan="1" colspan="1">0.304</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SVC</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.976</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">IC</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.994</td></tr></tbody></table><table-wrap-foot><fn id="TFN01t04"><label>SVC</label><p>: slow vital capacity</p></fn><fn id="TFN02t04"><label>IC</label><p>: inspiratory capacity</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec sec-type="discussion"><title>Discussion</title><p>In the present study, we propose upper limits for random short-term variations in
parameters assessed by SVC and FVC maneuvers in a sample of patients with airflow
obstruction. The variations in FEV<sub>1</sub> were found to be the same as those found
in previous studies. However, values for variations in FVC, when expressed as percentage
of change from baseline values, were lower. This is the first study to derive values for
changes in SVC and IC from a large sample.</p><p>Regarding the use of bronchodilators in a pulmonary function laboratory
setting,<sup>(</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> some questions remain:</p><p>
<list list-type="bullet"><list-item><p>What are the most appropriate parameters to express bronchodilator
response?</p></list-item><list-item><p>What is the best way to express the changes occurring after medication use?</p></list-item><list-item><p>What is the threshold that correlates with clinically significant outcomes?</p></list-item></list>
</p><p>Because it has the greatest sensitivity, the lowest variability, and the best
reproducibility, FEV<sub>1</sub> is the most widely used spirometric
parameter.<sup>(</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> The ATS and the ERS proposed FEV<sub>1 </sub>and FVC
increases of at least 0.20 L and of 12% of change from baseline values<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup> on
the basis of two studies.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B01" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup> One of those studies evaluated the changes
occurring after the administration of placebo in 40 patients.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup> The 95% CI
for FEV<sub>1</sub> was 0.18 L when expressed in absolute values and 12.3% when
expressed as percentage of change from baseline values. In the present study, these
values were 0.19 L and 12.3%, respectively, and, when derived from the 95th percentile,
0.16 and 12.7%. In patients with low FEV<sub>1</sub> values, the change in
FEV<sub>1</sub> after bronchodilator use commonly exceeds the limit of 12% of change
from the baseline value. Therefore, it has been suggested that absolute and relative
changes should be considered when evaluating the bronchodilator response. In the same
study,<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup> the upper limits for FVC were 0.34 L (absolute value) and 14.9%
(percentage of change from the baseline value). In the present study, the FVC values
derived from the 95% CI were 0.20 L and 7.3%, whereas those derived from the 95th
percentile were 0.23 L and 6.5%. After rounding these values, we propose that the upper
limits be set at 0.20 L and 7%. The ATS and the ATS/ERS<sup>(</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>,</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup> have stated that
the variations in FVC should be the same as those in FEV<sub>1</sub>, probably on the
basis of the expected short-term variability in FEV<sub>1</sub> and FVC in spirometric
maneuvers. Although the upper limit for absolute changes in FVC found in the present
study is similar to those suggested by the ATS, the values for the percentage of change
from baseline values are much lower. This will increase the sensitivity of FVC for
detecting changes in lung function in a pulmonary function laboratory setting. In
another study,<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup> 150 patients with obstructive disease underwent two
spirometric tests, 20 minutes apart. The increases in FEV<sub>1</sub> and FVC required
in order to exclude a random variation by 95% CI were 0.16 L and 0.33 L, respectively.
In a more recent study, FEV<sub>1</sub> and FVC variations were evaluated after the
administration of placebo in 98 patients with COPD.<sup>(</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> The upper limit was
found to be 0.18 L for FEV<sub>1</sub> and 0.28 L for FVC.</p><p>The most common ways of expressing the bronchodilator response are absolute changes,
percentage of change from baseline values, and percentage of predicted values.
Measurements based on predicted values have the best reproducibility and are the least
dependent on baseline values.<sup>(</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>)</sup> The values derived in the present study
suggest that increases &#x02265; 7% in the predicted FVC and FEV<sub>1</sub> values exceed the
natural variability and can therefore be considered significant. For the sake of the
reproducibility of the maneuvers, we believe that changes &#x02265; 0.20 L should also be
present in order to characterize a significant response to bronchodilator use.</p><p>The bronchodilator response evaluated by FEV<sub>1</sub> has few, if any, clinical
implications for COPD. The bronchodilator response varies according to the
setting.<sup>(</sup>
<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup> The lack of response in a laboratory setting does not
translate to a lack of clinical response to bronchodilators or inhaled corticosteroids,
as evaluated by short-term relief of dyspnea, long-term relief of dyspnea, improved
quality of life, improved exercise capacity, and changes in
FEV<sub>1</sub>.<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup>
</p><p>Two types of studies have been used in order to derive cut-off points intended to
characterize a significant bronchodilator response. Post-bronchodilator variations can
be considered significant if they exceed those observed in individuals without lung
disease or if they exceed the spontaneous variation observed after the administration of
placebo in patients with airflow limitation, such as those investigated in the present
study. In individuals without lung disease, FEV<sub>1</sub> increases by less than 10%
after bronchodilator use.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B18" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>,</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup> This cut-off point has been used for
distinguishing between asthma and COPD patients in some studies.<sup>(</sup>
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>,</sup>
<xref rid="B21" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>)</sup>
However, this limit can be exceeded in some patients with COPD, especially if a
combination of beta-agonists and anticholinergic agents is used.<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>22</sup>
</xref>
<sup>)</sup>
</p><p>Hyperinflation is a physiological change that is characteristic of many patients with
COPD. Airway obstruction leads to progressive air trapping during exhalation, as well as
leading to hyperinflation. These changes result in reduced resting IC, increased work of
breathing, and lower exercise tolerance.<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>,</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>)</sup> Dynamic hyperinflation has been
shown to be an independent predictor of decreased daily physical activity and mortality
due to respiratory failure in patients with COPD.<sup>(</sup>
<xref rid="B23" ref-type="bibr">
<sup>23</sup>
</xref>
<sup>)</sup>
</p><p>Bronchodilators reduce hyperinflation at rest and during exercise.<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> It
is possible that patients with COPD who do not show a significant response to
bronchodilators as assessed by flow (FEV<sub>1</sub>) will show a significant lung
volume response as assessed by increased SVC and IC.<sup>(</sup>
<xref rid="B24" ref-type="bibr">
<sup>24</sup>
</xref>
<sup>)</sup> Increased IC has
been associated with decreased hyperinflation and improved exercise
tolerance.<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>-</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> Many studies involving different classes of
bronchodilators have shown associations among increased IC, improved exercise tolerance,
and reduced dyspnea in COPD patients.<sup>(</sup>
<xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>
<sup>)</sup> However, changes in IC after
placebo administration are poorly characterized. In a study involving 26 patients with
asthma or COPD, the proposed limit for IC changes after placebo administration was a 9%
increase from baseline values or 220 mL.<sup>(</sup>
<xref rid="B06" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup> In two studies, an increase of
more than 0.3 L in IC was associated with a significant improvement in exercise
tolerance in patients with COPD.<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> In the present study, IC increases of
more than 15% in relation to the baseline values, of more than 12% in the predicted
values, and of 0.3 L were found to constitute the upper limit for IC after the
administration of placebo, values that are similar to those found in those
studies.<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> For SVC, increases of more than 0.25 L, of more than 10% in
relation to baseline values, or of more than 7% in the predicted values can be
considered significant.</p><p>Bronchodilator responses can be categorized as flow responses or volume responses. When
post-bronchodilator changes in FEV<sub>1</sub> are proportional to the
post-bronchodilator changes in FVC, they can reflect lung volume recruitment and should
be considered volume responses.<sup>(</sup>
<xref rid="B26" ref-type="bibr">
<sup>26</sup>
</xref>
<sup>)</sup> Although FEV<sub>1</sub> and FVC are
volume measurements, post-bronchodilator variations in these measurements can reflect
increased expiratory flow. An isolated post-bronchodilator variation in FEV<sub>1</sub>
probably reflects bronchial dilation primarily of the central airways, whereas an
isolated post-bronchodilator variation in FVC is indicative of bronchial dilation
primarily of the peripheral airways. Patients with more severe airflow obstruction
commonly show an isolated FVC response,<sup>(</sup>
<xref rid="B27" ref-type="bibr">
<sup>27</sup>
</xref>
<sup>)</sup> which reflects the emptying of
very slow lung compartments. Therefore, FEV<sub>1</sub> and FVC both also reflect
changes in flow, albeit in different segments of the tracheobronchial tree. It is
therefore not surprising that we found a correlation between FEV<sub>1</sub> changes and
FVC changes in the present study, those changes having shared a common factor (factor 1)
on factor analysis. In addition, FVC correlated and clustered with SVC on factor
analysis (factor 2). A volume response is characterized by an increase in SVC and in
FVC.</p><p>Interestingly, our factor analysis showed no association between variations in IC and
variations in SVC, although a significant but weak correlation was found between those
two variables. In patients with lung hyperinflation, a reduction in RV is expected after
the use of a bronchodilator, reflected by an increase in SVC.<sup>(</sup>
<xref rid="B28" ref-type="bibr">
<sup>28</sup>
</xref>
<sup>,</sup>
<xref rid="B29" ref-type="bibr">
<sup>29</sup>
</xref>
<sup>)</sup> However,
studies including unselected patients have found a poor but significant correlation
between variations in RV and variations in SVC.<sup>(</sup>
<xref rid="B30" ref-type="bibr">
<sup>30</sup>
</xref>
<sup>)</sup> It is known that TLC can
decrease after bronchodilator use, and this interferes with the abovementioned
correlation.<sup>(</sup>
<xref rid="B28" ref-type="bibr">
<sup>28</sup>
</xref>
<sup>)</sup> The changes in SVC after bronchodilator use are inferior
to the variation in IC in predicting exercise capacity improvement in COPD
patients.<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> The real operational limit for volume expansion in air
flow during exercise is IC rather than SVC. Although FVC also increases with the
reduction in RV after bronchodilator use, FVC is inferior to SVC because it is
influenced by thoracic gas compression during forced expiration (as is FEV<sub>1</sub>).
This finding is made even more evident with accentuated hyperinflation.<sup>(</sup>
<xref rid="B24" ref-type="bibr">
<sup>24</sup>
</xref>
<sup>)</sup>
</p><p>One of the possible limitations of the present study is the inclusion of a large
proportion of female asthma patients with mild airflow obstruction. However, there were
no differences between the patients with asthma and those with COPD in terms of the
variations in the parameters studied, and there were no correlations between
FEV<sub>1</sub>% and the variation in FEV<sub>1</sub> after the administration of
placebo.</p><p>In conclusion, we established cut-off points for changes in parameters derived from SVC
and FVC maneuvers performed after the administration of placebo in a large sample of
patients with airflow obstruction. On factor analysis, these parameters clustered into
three dimensions, expressing changes in flows, volumes, and dynamic hyperinflation.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p>Financial support: None.</p></fn><fn id="fn01" fn-type="supported-by"><label>*</label><p> Study carried out at the S&#x000e3;o Paulo Hospital for State Civil Servants, S&#x000e3;o Paulo,
Brazil.</p></fn><fn id="fn02" fn-type="other"><label>**</label><p> A vers&#x000e3;o completa em portugu&#x000ea;s deste artigo est&#x000e1; dispon&#x000ed;vel em
www.jornaldepneumologia.com.br</p></fn></fn-group><ref-list><title>References</title><ref id="B01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sourk</surname><given-names>RL</given-names></name><name><surname>Nugent</surname><given-names>KM</given-names></name></person-group><article-title>Bronchodilator testing: confidence intervals derived
from placebo inhalations</article-title><source>Am Rev Respir Dis</source><year>1983</year><volume>128</volume><issue>1</issue><fpage>153</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">6870056</pub-id></element-citation></ref><ref id="B02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tweeddale</surname><given-names>PM</given-names></name><name><surname>Alexander</surname><given-names>F</given-names></name><name><surname>McHardy</surname><given-names>GJ</given-names></name></person-group><article-title>Short term variability in FEV1 and bronchodilator
responsiveness in patients with obstructive ventilatory defects</article-title><source>Thorax</source><year>1987</year><volume>42</volume><issue>7</issue><fpage>487</fpage><lpage>490</lpage><!--<pub-id pub-id-type="pmcid">460802</pub-id>--><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/thx.42.7.487">http://dx.doi.org/10.1136/thx.42.7.487</ext-link><pub-id pub-id-type="pmid">3438892</pub-id></element-citation></ref><ref id="B03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Thoracic Society</collab></person-group><article-title>Standardization of Spirometry, 1994
Update</article-title><source>Am J Respir Crit Care Med</source><year>1995</year><volume>152</volume><issue>3</issue><fpage>1107</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">7663792</pub-id></element-citation></ref><ref id="B04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrino</surname><given-names>R</given-names></name><name><surname>Viegi</surname><given-names>G</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name><name><surname>Crapo</surname><given-names>RO</given-names></name><name><surname>Burgos</surname><given-names>F</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><etal/></person-group><article-title>Interpretative strategies for lung function
tests</article-title><source>Eur Respir J.</source><year>2005</year><volume>26</volume><issue>5</issue><fpage>948</fpage><lpage>968</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09031936.05.00035205">http://dx.doi.org/10.1183/09031936.05.00035205</ext-link><pub-id pub-id-type="pmid">16264058</pub-id></element-citation></ref><ref id="B05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>PL</given-names></name><name><surname>Quanjer</surname><given-names>PH</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>Kerstjens</surname><given-names>HA</given-names></name><name><surname>Ko&#x000eb;ter</surname><given-names>GH</given-names></name><name><surname>Dekhuijzen</surname><given-names>PN</given-names></name><etal/></person-group><article-title>Interpretation of bronchodilator response in patients
with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease
(CNSLD) Study Group</article-title><source>Thorax</source><year>1992</year><volume>47</volume><issue>6</issue><fpage>429</fpage><lpage>436</lpage><!--<pub-id pub-id-type="pmcid">463807</pub-id>--><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/thx.47.6.429">http://dx.doi.org/10.1136/thx.47.6.429</ext-link><pub-id pub-id-type="pmid">1496502</pub-id></element-citation></ref><ref id="B06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrino</surname><given-names>R</given-names></name><name><surname>Rodarte</surname><given-names>JR</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name></person-group><article-title>Assessing the reversibility of airway
obstruction</article-title><source>Chest</source><year>1998</year><volume>114</volume><issue>6</issue><fpage>1607</fpage><lpage>1612</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.114.6.1607">http://dx.doi.org/10.1378/chest.114.6.1607</ext-link><pub-id pub-id-type="pmid">9872196</pub-id></element-citation></ref><ref id="B07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Carballeira</surname><given-names>M</given-names></name><name><surname>Heredia</surname><given-names>JL</given-names></name><name><surname>Ru&#x000e9;</surname><given-names>M</given-names></name><name><surname>Quintana</surname><given-names>S</given-names></name><name><surname>Almagro</surname><given-names>P</given-names></name></person-group><article-title>The bronchodilator test in chronic obstructive pulmonary
disease: interpretation methods</article-title><source>Respir Med</source><year>2007</year><volume>101</volume><issue>1</issue><fpage>34</fpage><lpage>42</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.rmed.2006.04.018">http://dx.doi.org/10.1016/j.rmed.2006.04.018</ext-link><pub-id pub-id-type="pmid">16762537</pub-id></element-citation></ref><ref id="B08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belman</surname><given-names>MJ</given-names></name><name><surname>Botnick</surname><given-names>WC</given-names></name><name><surname>Shin</surname><given-names>JW</given-names></name></person-group><article-title>Inhaled bronchodilators reduce dynamic hyperinflation
during exercise in patients with chronic obstructive pulmonary
disease</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>153</volume><issue>3</issue><fpage>967</fpage><lpage>975</lpage><pub-id pub-id-type="pmid">8630581</pub-id></element-citation></ref><ref id="B09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>DE</given-names></name><name><surname>Lam</surname><given-names>M</given-names></name><name><surname>Webb</surname><given-names>KA</given-names></name></person-group><article-title>Measurement of symptoms, lung hyperinflation, and
endurance during exercise in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>158</volume><issue>5</issue><issue-part>Pt 1</issue-part><fpage>1557</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">9817708</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Pereira</surname><given-names>CA</given-names></name></person-group><article-title xml:lang="pt">Resposta a broncodilatador na espirometria: que
par&#x000e2;metros e valores s&#x000e3;o clinicamente relevantes em doen&#x000e7;as
obstrutivas?</article-title><source>J. Pneumol</source><year>2001</year><volume>27</volume><issue>1</issue><fpage>35</fpage><lpage>47</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MR</given-names></name><name><surname>Hankinson</surname><given-names>J</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name><name><surname>Burgos</surname><given-names>F</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Coates</surname><given-names>A</given-names></name><etal/></person-group><article-title>Standardisation of spirometry</article-title><source>Eur Respir J</source><year>2005</year><volume>26</volume><issue>2</issue><fpage>319</fpage><lpage>338</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09031936.05.00034805">http://dx.doi.org/10.1183/09031936.05.00034805</ext-link><pub-id pub-id-type="pmid">16055882</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>CA</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Rodrigues</surname><given-names>SC</given-names></name></person-group><article-title>New reference values for forced spirometry in white
adults in Brazil</article-title><source>J Bras Pneumol</source><year>2007</year><volume>33</volume><issue>4</issue><fpage>397</fpage><lpage>406</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1806-37132007000400008">http://dx.doi.org/10.1590/S1806-37132007000400008</ext-link><pub-id pub-id-type="pmid">17982531</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neder</surname><given-names>JA</given-names></name><name><surname>Andreoni</surname><given-names>S</given-names></name><name><surname>Castelo-Filho</surname><given-names>A</given-names></name><name><surname>Nery</surname><given-names>LE</given-names></name></person-group><article-title>Reference values for lung function tests. I. Static
volumes</article-title><source>Braz J Med Biol Res</source><year>1999</year><volume>32</volume><issue>6</issue><fpage>703</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">10412549</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Peat</surname><given-names>J</given-names></name><name><surname>Barton</surname><given-names>B</given-names></name></person-group><article-title>Continuous variables: descriptive
statistics</article-title><person-group person-group-type="editor"><name><surname>Peat</surname><given-names>J</given-names></name><name><surname>Barton</surname><given-names>B</given-names></name></person-group><source>Medical Statistics</source><publisher-loc>Malden</publisher-loc><publisher-name>Blackwell Publishing</publisher-name><fpage>24</fpage><lpage>50</lpage><year>2005</year></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthonisen</surname><given-names>NR</given-names></name><name><surname>Wright</surname><given-names>EC</given-names></name></person-group><article-title>Bronchodilator response in chronic obstructive pulmonary
disease</article-title><source>Am Rev Respir Dis</source><year>1986</year><volume>133</volume><issue>5</issue><fpage>814</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">3706890</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerstjens</surname><given-names>HA</given-names></name><name><surname>Brand</surname><given-names>PL</given-names></name><name><surname>Quanjer</surname><given-names>PH</given-names></name><name><surname>van der Bruggen-Bogaarts</surname><given-names>BA</given-names></name><name><surname>Ko&#x000eb;ter</surname><given-names>GH</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name></person-group><article-title>Variability of bronchodilator response and effects of
inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study
Group</article-title><source>Thorax</source><year>1993</year><volume>48</volume><issue>7</issue><fpage>722</fpage><lpage>729</lpage><!--<pub-id pub-id-type="pmcid">464656</pub-id>--><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/thx.48.7.722">http://dx.doi.org/10.1136/thx.48.7.722</ext-link><pub-id pub-id-type="pmid">8153921</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Rennard</surname><given-names>SI</given-names></name></person-group><article-title>What have we learned from large drug treatment trials in
COPD?</article-title><source>Lancet</source><year>2007</year><volume>370</volume><issue>9589</issue><fpage>774</fpage><lpage>785</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(07)61381-6">http://dx.doi.org/10.1016/S0140-6736(07)61381-6</ext-link><pub-id pub-id-type="pmid">17765527</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannessen</surname><given-names>A</given-names></name><name><surname>Lehmann</surname><given-names>S</given-names></name><name><surname>Omenaas</surname><given-names>ER</given-names></name><name><surname>Eide</surname><given-names>GE</given-names></name><name><surname>Bakke</surname><given-names>PS</given-names></name><name><surname>Gulsvik</surname><given-names>A</given-names></name></person-group><article-title>Post-bronchodilator spirometry reference values in
adults and implications for disease management</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><issue>12</issue><fpage>1316</fpage><lpage>1325</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.200601-023OC">http://dx.doi.org/10.1164/rccm.200601-023OC</ext-link><pub-id pub-id-type="pmid">16556696</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kainu</surname><given-names>A</given-names></name><name><surname>Lindqvist</surname><given-names>A</given-names></name><name><surname>Sarna</surname><given-names>S</given-names></name><name><surname>Lundb&#x000e4;ck</surname><given-names>B</given-names></name><name><surname>Sovij&#x000e4;rvi</surname><given-names>A</given-names></name></person-group><article-title>FEV1 response to bronchodilation in an adult urban
population</article-title><source>Chest</source><year>2008</year><volume>134</volume><issue>2</issue><fpage>387</fpage><lpage>393</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.07-2207">http://dx.doi.org/10.1378/chest.07-2207</ext-link><pub-id pub-id-type="pmid">18403671</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meslier</surname><given-names>N</given-names></name><name><surname>Racineux</surname><given-names>JL</given-names></name><name><surname>Six</surname><given-names>P</given-names></name><name><surname>Lockhart</surname><given-names>A</given-names></name></person-group><article-title>Diagnostic value of reversibility of chronic airway
obstruction to separate asthma from chronic bronchitis: a statistical
approach</article-title><source>Eur Respir J</source><year>1989</year><volume>2</volume><issue>6</issue><fpage>497</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">2744134</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvestri</surname><given-names>IC</given-names></name><name><surname>Pereira</surname><given-names>CA</given-names></name><name><surname>Rodrigues</surname><given-names>SC</given-names></name></person-group><article-title>Comparison of spirometric changes in the response to
bronchodilators of patients with asthma or chronic obstructive pulmonary
disease</article-title><source>J Bras Pneumol</source><year>2008</year><volume>34</volume><issue>9</issue><fpage>675</fpage><lpage>682</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1806-37132008000900007">http://dx.doi.org/10.1590/S1806-37132008000900007</ext-link><pub-id pub-id-type="pmid">18982204</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Burge</surname><given-names>PS</given-names></name><name><surname>Spencer</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name></person-group><article-title>Bronchodilator reversibility testing in chronic
obstructive pulmonary disease</article-title><source>Thorax</source><year>2003</year><volume>58</volume><issue>8</issue><fpage>659</fpage><lpage>664</lpage><!--<pub-id pub-id-type="pmcid">1746778</pub-id>--><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/thorax.58.8.659">http://dx.doi.org/10.1136/thorax.58.8.659</ext-link><pub-id pub-id-type="pmid">12885978</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casanova</surname><given-names>C</given-names></name><name><surname>Cote</surname><given-names>C</given-names></name><name><surname>de Torres</surname><given-names>JP</given-names></name><name><surname>Aguirre-Jaime</surname><given-names>A</given-names></name><name><surname>Marin</surname><given-names>JM</given-names></name><name><surname>Pinto-Plata</surname><given-names>V</given-names></name><etal/></person-group><article-title>Inspiratory-to-total lung capacity ratio predicts
mortality in patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2005</year><volume>171</volume><issue>6</issue><fpage>591</fpage><lpage>597</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.200407-867OC">http://dx.doi.org/10.1164/rccm.200407-867OC</ext-link><pub-id pub-id-type="pmid">15591470</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>PP</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name></person-group><article-title>The volumetric response to bronchodilators in stable
chronic obstructive pulmonary disease</article-title><source>COPD</source><year>2008</year><volume>5</volume><issue>3</issue><fpage>147</fpage><lpage>152</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/15412550802092928">http://dx.doi.org/10.1080/15412550802092928</ext-link><pub-id pub-id-type="pmid">18568838</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>DE</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Vincken</surname><given-names>W</given-names></name><name><surname>Puente-Maestu</surname><given-names>L</given-names></name><name><surname>Swales</surname><given-names>J</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effect of indacaterol on exercise endurance and lung
hyperinflation in COPD</article-title><source>Respir Med</source><year>2011</year><volume>105</volume><issue>7</issue><fpage>1030</fpage><lpage>1036</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.rmed.2011.03.014">http://dx.doi.org/10.1016/j.rmed.2011.03.014</ext-link><pub-id pub-id-type="pmid">21498063</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>DE</given-names></name></person-group><article-title>Assessment of bronchodilator efficacy in symptomatic
COPD: is spirometry useful?</article-title><source>Chest</source><year>2000</year><volume>117</volume><issue>2 Suppl</issue><fpage>42S</fpage><lpage>47S</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.117.2_suppl.42S">http://dx.doi.org/10.1378/chest.117.2_suppl.42S</ext-link><pub-id pub-id-type="pmid">10673474</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schermer</surname><given-names>T</given-names></name><name><surname>Heijdra</surname><given-names>Y</given-names></name><name><surname>Zadel</surname><given-names>S</given-names></name><name><surname>van den Bemt</surname><given-names>L</given-names></name><name><surname>Boonman-de Winter</surname><given-names>L</given-names></name><name><surname>Dekhuijzen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Flow and volume responses after routine salbutamol
reversibility testing in mild to very severe COPD</article-title><source>Respir Med</source><year>2007</year><volume>101</volume><issue>6</issue><fpage>1355</fpage><lpage>1362</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.rmed.2006.09.024">http://dx.doi.org/10.1016/j.rmed.2006.09.024</ext-link><pub-id pub-id-type="pmid">17098407</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>MF</given-names></name><name><surname>O'Donnell</surname><given-names>DE</given-names></name><name><surname>Forkert</surname><given-names>L</given-names></name></person-group><article-title>Response of lung volumes to inhaled salbutamol in a
large population of patients with severe hyperinflation</article-title><source>Chest</source><year>2002</year><volume>121</volume><issue>4</issue><fpage>1042</fpage><lpage>1050</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.121.4.1042">http://dx.doi.org/10.1378/chest.121.4.1042</ext-link><pub-id pub-id-type="pmid">11948031</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellamy</surname><given-names>D</given-names></name><name><surname>Hutchison</surname><given-names>DC</given-names></name></person-group><article-title>The effects of salbutamol aerosol on lung function in
patients with pulmonary emphysema</article-title><source>Br J Dis Chest</source><year>1981</year><volume>75</volume><issue>2</issue><fpage>190</fpage><lpage>196</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0007-0971(81)90052-8">http://dx.doi.org/10.1016/0007-0971(81)90052-8</ext-link><pub-id pub-id-type="pmid">7023528</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balestra</surname><given-names>AM</given-names></name><name><surname>Bingisser</surname><given-names>RB</given-names></name><name><surname>Chhajed</surname><given-names>PN</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name><name><surname>Leuppi</surname><given-names>JD</given-names></name></person-group><article-title>Bronchodilator response in residual volume in
irreversible airway obstruction</article-title><source>Swiss Med Wkly</source><year>2008</year><volume>138</volume><issue>17-18</issue><fpage>251</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">18481230</pub-id></element-citation></ref></ref-list></back></article>